Valuation: Anika Therapeutics, Inc.

Market Cap 287M 256M 236M 214M 401M 27.21B 408M 2.85B 1.13B 14.26B 1.08B 1.05B 44.95B P/E 2026 *
612x
P/E 2027 * 71.4x
Enterprise Value 287M 256M 236M 214M 401M 27.21B 408M 2.85B 1.13B 14.26B 1.08B 1.05B 44.95B EV / Sales 2026 *
2.36x
EV / Sales 2027 * 2.24x
Free-Float
79.73%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
1 week+7.21%
Current month+8.95%
1 month+5.13%
3 months+46.01%
6 months+38.91%
Current year+122.89%
1 week 19.87
Extreme 19.87
21.45
1 month 18.11
Extreme 18.11
21.45
Current year 9.01
Extreme 9.0101
22.88
1 year 9.01
Extreme 9.0101
22.88
3 years 7.87
Extreme 7.8701
29.12
5 years 7.87
Extreme 7.8701
45.81
10 years 7.87
Extreme 7.8701
75.72
Manager TitleAgeSince
Chief Executive Officer 41 2026-01-31
Chief Tech/Sci/R&D Officer - 2023-08-31
Chief Tech/Sci/R&D Officer - 2019-10-13
Director TitleAgeSince
Chairman 62 2026-01-31
Chairman 65 2024-02-23
Director/Board Member 64 2020-09-02
Date Insider Type Main position Quantity % Market Cap. Importance
8/4/26 Buy

Director

1,000 0.0075%
6/3/26 Exercice

Chief Executive Officer

29,449 0.2213%
5/1/26 Buy

Director

5,000 0.0373%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+7.21%+121.97%+15.16% 276M
+1.16%-1.13%-17.92%+8.27% 177B
-1.22%+0.70%+1.27%+31.80% 118B
+0.02%+4.24%-19.82%+16.53% 118B
+2.29%+17.36%-41.94%+9.49% 91.21B
-2.21%-2.91%+0.74%+75.30% 64.59B
-1.06%+1.75%+13.50%+80.00% 56.13B
-0.75%+3.73%+6.64%-22.28% 54.59B
-1.13%+0.00%-12.25%+31.02% 43.6B
+0.17%+5.85%-4.92%-10.64% 33.95B
Average -0.12%+3.74%+4.73%+23.46% 75.78B
Weighted average by Cap. -0.02%+3.30%-11.46%+22.66%

Financials

2026 *2027 *
Net sales 122M 109M 100M 90.94M 170M 11.55B 173M 1.21B 478M 6.05B 457M 447M 19.07B 128M 115M 106M 95.89M 179M 12.18B 182M 1.27B 504M 6.38B 481M 471M 20.11B
Net income 482K 431K 398K 361K 675K 45.8M 686K 4.79M 1.9M 24M 1.81M 1.77M 75.66M 4.17M 3.73M 3.44M 3.12M 5.84M 396M 5.93M 41.43M 16.4M 208M 15.66M 15.33M 654M
Net Debt - -
Projected Income Statement - Annual - Anika Therapeutics, Inc.
Logo Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Employees
235
Date Price Change Volume
26-10-23 US$21.42 +1.56% 59,202
26-10-22 US$21.09 +2.38% 61,425
26-10-21 US$20.60 +0.78% 51,291
26-10-20 US$20.44 +1.09% 362,961
26-10-19 US$20.22 +1.20% 66,535
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Anika Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
21.42USD
Average target price
23.00USD
Spread / Average Target
+7.38%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Anika Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ANIK Stock